In this issue:
Early combined immunosuppression effective in CD
IBD treatment may weaken response to HBV vaccine
Higher risk of invasive pneumococcal disease in IBD
Enteral nutrition maintains remission in CD
Correcting gut microbiota may improve IBD symptoms
Probiotic E. coli strain Nissle 1917 in IBS . . . no therapeutic effects after 6 or 12 weeks
Gut inflammation and microbiome in SpA
Programmable probiotics for detecting cancer in urine
Predictive overbooking prevents clinic no-shows
Avoiding dietary fibre increases risk of CD
Science Blog: The role of RAS in IBD
Please login below to download this issue (PDF)